Recombinant Factor C (rFC) vs LAL: A Multi-Sample Comparability Study for Endotoxin Testing

Why Endotoxin Testing Matters in Biopharmaceutical Manufacturing

Endotoxin control is a fundamental requirement throughout biopharmaceutical development and manufacturing. For products such as recombinant proteins, monoclonal antibodies, and cell and gene therapies, endotoxin levels have a direct impact on product safety, consistency, and clinical risk. As product modalities continue to diversify and manufacturing processes become more complex, selecting a robust and reliable endotoxin testing method has become an increasingly important aspect of quality control.

Today, endotoxin testing is primarily based on two technical approaches. The traditional approach is represented by the Limulus Amebocyte Lysate (LAL) dynamic chromogenic assay, while newer methods are represented by recombinant Factor C (rFC)–based assays. Both methods are recognized by major pharmacopeias. However, differences in assay design, reagent composition, and long-term sustainability have prompted increasing industry interest in evaluating the comparability between rFC and LAL assays for modern bacterial endotoxin testing (BET) workflows.

LAL vs rFC: Overview of Endotoxin Testing Methods

• LAL Dynamic Chromogenic Assay

The LAL dynamic chromogenic assay has been widely used in routine quality control for decades. It relies on an enzyme cascade initiated by Factor C present in horseshoe crab lysate. In the presence of endotoxin, this cascade leads to a measurable colorimetric reaction, which is monitored kinetically to determine endotoxin concentration. The method offers high sensitivity and a broad working range and has been successfully applied to protein therapeutics, antibodies, and injectable formulations. However, as sample matrices become more complex, practical challenges may arise, including matrix-related interference, lot-to-lot variability, and dependence on natural horseshoe crab resources.

• Recombinant Factor C (rFC) Assay

The rFC assay represents a newer generation of endotoxin testing technology. It uses recombinantly expressed Factor C as the sole endotoxin-responsive component, providing a direct and highly specific response to endotoxin without involving a multi-enzyme cascade. Because rFC reagents are produced recombinantly, the method offers improved batch consistency, a more stable supply chain, and enhanced environmental sustainability. As a result, rFC-based assays are gaining increasing acceptance within the global biopharmaceutical industry.

Comparison of LAL Assay and Recombinant Factor C Assay Detection Procedures

Multi-Sample Comparability Study Design for rFC and LAL Assays

To evaluate the quantitative consistency between the LAL dynamic chromogenic assay and the rFC assay, the ACROBiosystems research team conducted a comprehensive comparability study using multiple representative sample types.

The mean endotoxin values obtained from four commercially available LAL dynamic chromogenic kits were used as a reference. Parallel testing was performed on protein samples, antibody samples, injectable solutions, cell lysates, and commonly used buffer systems. This study design was intended to closely reflect practical testing conditions encountered during biopharmaceutical development and manufacturing. Endotoxin results from the rFC assay were compared against LAL reference values, and result ratios were analyzed across sample matrices.

• rFC and LAL Comparability Data Summary

Key Comparability Findings Between rFC and LAL Endotoxin Assays

The study demonstrated strong agreement between the LAL dynamic chromogenic assay and the rFC assay across all tested sample types. Quantitative endotoxin results obtained using both methods were highly comparable, indicating equivalent overall detection performance.

Across multiple sample matrices, the ratio of endotoxin values generated by the rFC assay relative to those obtained with established LAL dynamic chromogenic assays consistently fell within a range of 50% to 200%. These findings confirm a high degree of comparability between the two methods under realistic testing conditions.

This multi-sample comparability study provides meaningful data support for biopharmaceutical companies evaluating endotoxin testing strategies, including method selection, method transfer, and analytical modernization. As regulatory expectations continue to evolve and sustainability considerations gain importance, reliable and scientifically sound endotoxin testing solutions are becoming an integral part of modern quality systems.

ACROBiosystems remains committed to supporting the biopharmaceutical industry through data-driven research and practical validation studies, helping advance quality control standards and ensure the safety and compliance of biopharmaceutical products.

Regulatory and Industry Relevance

With the implementation of USP <86> and increasing global acceptance of recombinant reagents, biopharmaceutical manufacturers are actively evaluating rFC as an alternative to traditional LAL assays. Demonstrating comparability across representative sample matrices is critical for endotoxin method validation, analytical method transfer, and global QC harmonization.

Take Action: Experience rFC Endotoxin Testing in Practice

• Request a Trial of Our Featured rFC Endotoxin Test Kit

Built on ACROBiosystems’ proprietary technology platform, the recombinant Factor C endotoxin test kit (Cat. No. RES-A056) based on an endpoint fluorescence assay enables rapid and reliable detection of bacterial endotoxins across a wide range of sample types. The assay delivers results comparable to established LAL methods while offering high sensitivity, high specificity, and excellent lot-to-lot consistency. Designed for use in pharmaceutical, medical device, and biopharmaceutical applications, this rFC kit supports stringent quality control requirements and provides a robust alternative for modern endotoxin testing workflows.

FAQ

Q: Is rFC equivalent to LAL for endotoxin testing?

A: Comparability studies across multiple biopharmaceutical sample types have demonstrated that rFC assays provide endotoxin results comparable to traditional LAL methods.

Q: Why are biopharmaceutical companies adopting rFC?

A: rFC assays offer high specificity, improved batch consistency, sustainable reagent supply, and reduced β-glucan interference compared with traditional LAL assays.

Q: Can rFC be used for complex biologics and CGT products?

A: Studies have shown that rFC assays perform reliably across recombinant proteins, antibodies, injectable formulations, buffers, and other complex biopharmaceutical matrices.

Endotoxin Testing Resource Series

Part 1: Strategies for Mitigating β-Glucan Interference in Endotoxin Detection

Part 2: Application of Recombinant Factor C Endotoxin Testing in Pharmaceutical Manufacturing

Part 3: Standards and Regulations for Recombinant Factor C Endotoxin Testing from a Pharmacopoeial Perspective

Part 4: Comparability Between Recombinant Factor C and Traditional LAL Assay in Endotoxin Detection

Part 5: A Comprehensive Guide to Sample Dilution Calculations for Recombinant Factor C Endotoxin Testing

Part 6: Key Considerations for Endotoxin Testing Experimental Procedures

Part 7: Interfering Factors in Endotoxin Testing

>>>Proven rFC Performance — Explore Our Full Validation Report